BASILEA PHARMACEUTICA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.5 CHF | +3.25% |
|
+9.34% | +26.06% |
| 03/05 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
| 09/04 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BASILEA PHARMACEUTICA AG | Other Biotechnology & Medical Research | +3.25% | +9.34% | +26.06% | -3.78% | +8.48% | 57Cr |  | |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- BSLN Stock
- Charts Basilea Pharmaceutica AG
- Comparison Chart
